WO1997034149A1 - Methode diagnostique de mycobacteriose et trousse d'essai immunologique - Google Patents
Methode diagnostique de mycobacteriose et trousse d'essai immunologique Download PDFInfo
- Publication number
- WO1997034149A1 WO1997034149A1 PCT/EP1997/001037 EP9701037W WO9734149A1 WO 1997034149 A1 WO1997034149 A1 WO 1997034149A1 EP 9701037 W EP9701037 W EP 9701037W WO 9734149 A1 WO9734149 A1 WO 9734149A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- lam
- mycobacterial
- patient
- urine
- diagnosing
- Prior art date
Links
- 208000027531 mycobacterial infectious disease Diseases 0.000 title claims abstract description 19
- 238000000034 method Methods 0.000 title claims abstract description 18
- 238000003018 immunoassay Methods 0.000 title claims abstract description 12
- 239000000427 antigen Substances 0.000 claims abstract description 20
- 102000036639 antigens Human genes 0.000 claims abstract description 20
- 108091007433 antigens Proteins 0.000 claims abstract description 20
- 210000002700 urine Anatomy 0.000 claims abstract description 17
- 241000187479 Mycobacterium tuberculosis Species 0.000 claims abstract description 11
- 206010036790 Productive cough Diseases 0.000 claims abstract description 10
- 210000003608 fece Anatomy 0.000 claims abstract description 10
- 210000003802 sputum Anatomy 0.000 claims abstract description 10
- 208000024794 sputum Diseases 0.000 claims abstract description 10
- 239000012634 fragment Substances 0.000 claims abstract description 9
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 9
- 201000008827 tuberculosis Diseases 0.000 claims abstract description 9
- 241000513886 Mycobacterium avium complex (MAC) Species 0.000 claims abstract description 8
- 238000003556 assay Methods 0.000 claims abstract description 7
- 230000000694 effects Effects 0.000 claims abstract description 6
- 238000012544 monitoring process Methods 0.000 claims abstract description 5
- 230000001954 sterilising effect Effects 0.000 claims abstract description 4
- 238000004659 sterilization and disinfection Methods 0.000 claims abstract description 4
- 238000002965 ELISA Methods 0.000 claims description 7
- 239000000243 solution Substances 0.000 claims description 5
- 238000003127 radioimmunoassay Methods 0.000 claims description 4
- 239000013641 positive control Substances 0.000 claims description 3
- 238000005406 washing Methods 0.000 claims description 3
- 239000007853 buffer solution Substances 0.000 claims description 2
- 238000003119 immunoblot Methods 0.000 claims description 2
- 239000013642 negative control Substances 0.000 claims description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 10
- 239000002953 phosphate buffered saline Substances 0.000 description 10
- 239000012528 membrane Substances 0.000 description 9
- 210000002421 cell wall Anatomy 0.000 description 6
- 238000012360 testing method Methods 0.000 description 5
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 239000005018 casein Substances 0.000 description 3
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 3
- 235000021240 caseins Nutrition 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000003118 sandwich ELISA Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 229920000057 Mannan Polymers 0.000 description 2
- 206010062207 Mycobacterial infection Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 2
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- GUPXYSSGJWIURR-UHFFFAOYSA-N 3-octoxypropane-1,2-diol Chemical compound CCCCCCCCOCC(O)CO GUPXYSSGJWIURR-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 208000036981 active tuberculosis Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- -1 aminoethyl Bio-Gel P-2 Chemical compound 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000006287 biotinylation Effects 0.000 description 1
- 238000007413 biotinylation Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- AEUTYOVWOVBAKS-UWVGGRQHSA-N ethambutol Chemical compound CC[C@@H](CO)NCCN[C@@H](CC)CO AEUTYOVWOVBAKS-UWVGGRQHSA-N 0.000 description 1
- 229960000285 ethambutol Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229960003350 isoniazid Drugs 0.000 description 1
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 238000006268 reductive amination reaction Methods 0.000 description 1
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 1
- 229960001225 rifampicin Drugs 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
- G01N33/5695—Mycobacteria
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
- G01N2400/10—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- G01N2400/50—Lipopolysaccharides; LPS
Definitions
- the present invention relates to a method of diagnosing a mycobacterial disease, a method of monitoring the effects of therapeutic treatment of a mycobacterial disease and an immunoassay kit for diagnosing a mycobacterial disease in a patient.
- mycobacteria causing diseases in man and the most important ones, which are pathogenic to humans, belong to the group Mycobacterium tuberculosis (TBC) and Mycobacterium avium complex (MAC). These bacteria have different, but closely related carbohydrate antigens on their cell walls, namely lipoarabinomannans (LAM), and arabinomannans (AM).
- LAM lipoarabinomannans
- AM arabinomannans
- One method of detecting a mycobacterial infection is based on detection of antibodies against LAM in a blood or serum sample form a patient ( Theuer CP, Chaisson RE, Bias D (1989), Am. Rev. Respir. Dis. 139 (4, Part 2) : A 395).
- antibodies against a bacterial antigen are used for diagnosing it is possible that a past infection and/or vaccination rather than an on-going infection or disease is detected.
- Mycobacterial diseases can be therapeutically treated by administration of certain antibiotics, such as Rifampicin, Etambutol, and Isoniazid.
- lipoarabinomannans and arabinomannans (AM), derived from Mycobacterium tuberculosis (TBC) and Mycobacterium avium complex (MAC)
- LAM lipoarabinomannans
- AM arabinomannans
- TBC Mycobacterium tuberculosis
- MAC Mycobacterium avium complex
- the present invention is directed to a method of diagnosing a mycobacterial disease in a patient typically caused by Mycobacterium tuberculosis (TBC) or Mycobacterium avium complex (MAC), wherein, in a sample of feces, sputum or urine from said patient, the presence of a mycobacterial antigen selected from the group consisting of lipoarabino- mannans (LAM), arabinomannans (AM), and fragments of LAM and AM, is determined.
- TBC Mycobacterium tuberculosis
- MAC Mycobacterium avium complex
- Said determination is preferably performed by the use of polyclonal or monoclonal antibodies directed against said mycobacterial antigen, and of an assay detecting antigen/antibody complexes formed.
- ELISA enzyme-linked immunosorbent assay
- RIA radioimmunoassay
- immunoblotting immunoblotting.
- the sample of feces, sputum or urine is pretreated by heat sterilization.
- the invention is further directed to an immunoassay kit, which comprises optionally labeled polyclonal or monoclonal antibodies directed against a mycobacterial antigen selected from the group consisting of lipoarabino- mannans (LAM), arabinomannans (AM), and fragments of LAM and AM.
- LAM lipoarabino- mannans
- AM arabinomannans
- the labels of the antibodies are selected in agreement with the diagnostic method to be used, e.g. an enzyme label when ELISA is to be used etc.
- said antibodies directed against said mycobacterial antigen has been coupled to a carrier.
- the carrier may be a solid support such as a plastic or glass surface, a membrane of e.g. derivatized carboxy cellulose, filter of e.g. Nylon or the like.
- the immunoassay kit may additionally comprise an optionally labeled second monoclonal or polyclonal antibody, a positive control, a negative control, and optionally buffer solution(s) and/or washing solution(s).
- the present invention is further directed to a method of monitoring the effects of therapeutic treatment of a mycobacterial disease in a patient typically caused by Mycobacterium tuberculosis (TBC) or Mycobacterium avium complex (MAC), wherein, in a sample of feces, sputum or urine from said patient, the presence and amount of a mycobacterial antigen selected from the group consisting of lipoarabinomannans (LAM), arabinomannans (AM), and fragments of LAM and AM, is determined at appropriate stages of said therapeutic treatment.
- LAM lipoarabinomannans
- AM arabinomannans
- fragments of LAM and AM fragments of LAM and AM
- a sandwich ELISA is used for the detection of mycobacterial antigens in a sample of urine from a tuberculosis patient.
- the wells of a microtiter plate were coated with 100 ⁇ l of (mono or polyclonal) antibodies against lipoarabinomannan (LAM) per well. After overnight incubation at room temperature, the unbound antibody was removed and the remaining free binding sites of the wells were blocked by 200 ml 0.5% casein for 1 h at 37°C. Excess casein was removed, the plate was washed 3 times with washing buffer (0.05% Tween 20 in PBS) and 100 ⁇ l of urine samples were added.
- washing buffer 0.05% Tween 20 in PBS
- biotinylated anti-LAM IgG (5 ⁇ g/ml in PBS), incubate the membrane for 30 min at room temperature.
- mice were given phosphate buffered saline (PBS). Urine samples were collected from the mice on the next day and analyzed by both catch-up ELISA 6
- Urine samples from 20 patients with active tuberculosis and from 3 patients with both HIV and Mycobacterium avium complex (MAC) were analyzed; all became positive in the test. 18 healthy control patients were also analyzed and the results were negative. Matched patients with other diseases (30 patients) were also included in these studies, and interestingly some of these control patients (5 patients, positive in the assay of the invention) who initially were clinically asserted to be none TB showed upon follow-up to either have TB or a more or less recent history of TB.
- LAM lipoarabinomannan
- Purified LAM may be used as a positive control in the immunoassay of the invention, and as starting material for the preparation of monospecific polyclonal antibodies against LAM (which will be exemplified below).
- Dry cell wall (5 g) from Mycobacterium tuberculosis is sonicated in Na-acetate buffer, pH 4.7, 5X3 min, followed by extraction with 80% phenol for 1 h at 70°C. After centrifugation for 30 min at 3500 rpm the phenolic phase is reextracted with water, the phenolic phase is discarded, and the aqueous phase is pooled with the aqueous phase from the centrifugation. The pooled aqueous phase is dialyzed against 3 x 5 liters of water overnight. Chromatography on octyl- Sepharose ® (Pharmacia , Sweden) yields 5 mg (0.1%) of LAM.
- Both monoclonal and polyclonal antibodies may be use in the immunoassay of the invention.
- the preparation of polyclonal antibodies starting with the bacterial cell wall, and monospecific polyclonal antibodies starting with LAM are exemplified.
- LAM (6.5 mg) is oxidized with 0.01 M NalO 4 for 7 min at 4°C in the dark. Excessive NalO 4 is eliminated by addition of ethylene glycol. Fragments of LAM are separated by gel chromatography. Coupling of the fragments to aminoethyl Bio-Gel P-2 ( Bio-Rad, USA) through reductive amination at room temperature, pH 8, for 5 days results in a 70% yield. Blockage of excessive amino groups was performed by acetylation with Na-acetate using a water soluble carbodiimide such as EDAC at room temperature, pH 4.5, for 17 h, followed by washing and subsequent equilibration of the column with PBS. Affinity-LAM column yields purified monospecific polyclonal anti-LAM IgG, which can be used instead of monoclonal antibodies in the immunoassay of the invention.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
L'invention a trait à une méthode diagnostique de mycobactériose chez un patient, causée, d'ordinaire, par le bacille tuberculeux (MAC) ou le complexe MAI. On vérifie, dans un échantillon de selles, d'expectorations ou d'urine, la présence d'un antigène mycobactérien appartenant au groupe constitué de lipoarabinomannes (LAM), d'arabinomannes (AM) ainsi que de fragments de LAM et d'AM, en faisant, par exemple, intervenir des anticorps polyclonaux ou monoclonaux dirigés contre cet antigène mycobactérien et en effectuant un dosage afin de déceler les complexes antigène-anticorps formés. Il est possible de pré-traiter par une stérilisation à chaud les échantillons de selles, d'expectorations ou d'urine. Cette invention concerne également une trousse d'essai immunologique à utiliser dans le cadre de cette méthode diagnostique ainsi que la marche à suivre pour contrôler les effets d'une thérapie d'une mycobactériose.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU20942/97A AU2094297A (en) | 1996-03-12 | 1997-03-03 | Method of diagnosing a mycobacterial disease and immunoassay kit |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9600949A SE9600949D0 (sv) | 1996-03-12 | 1996-03-12 | Method of diagnosing a mycobacterial disease and immunoassay kit |
| SE9600949-3 | 1996-03-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO1997034149A1 true WO1997034149A1 (fr) | 1997-09-18 |
Family
ID=20401759
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP1997/001037 WO1997034149A1 (fr) | 1996-03-12 | 1997-03-03 | Methode diagnostique de mycobacteriose et trousse d'essai immunologique |
Country Status (3)
| Country | Link |
|---|---|
| AU (1) | AU2094297A (fr) |
| SE (1) | SE9600949D0 (fr) |
| WO (1) | WO1997034149A1 (fr) |
Cited By (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0952849A1 (fr) * | 1996-12-31 | 1999-11-03 | New York University | Depistage precoce des maladies mycobacteriennes |
| WO2001027613A3 (fr) * | 1999-10-12 | 2001-10-18 | Connex Ges Zur Optimierung Von | Procede de detection ameliore de micro-organismes acido-resistants dans les selles |
| EP1158991A1 (fr) * | 1999-03-15 | 2001-12-05 | The Malaghan Institute of Medical Research | Traitement de l'asthme |
| EP1329718A2 (fr) * | 2002-01-10 | 2003-07-23 | Becton, Dickinson and Company | Methodes et appareils pour rassembler et preparer des echantillons afin de detecter des mycobacteries et leurs antigenes |
| WO2006012413A1 (fr) | 2004-07-20 | 2006-02-02 | Chemogen, Inc. | Anticorps enrichi pour detecter une infection mycobacterienne, procedes pour l'utiliser et test diagnostique utilisant celui-ci |
| EP1710584A1 (fr) * | 2003-12-22 | 2006-10-11 | Seikagaku Corporation | Procede permettant de mesurer le lipoarabinomannane et applications de ce procede |
| EP1882939A1 (fr) * | 2006-07-27 | 2008-01-30 | The Jordanian Pharmaceutical Manufacturing Co. | Ventouse de détection antigène immuno-chromatographique urinaire |
| WO2009117462A1 (fr) * | 2008-03-18 | 2009-09-24 | Wisconsin Alumini Research Foundation | Test de criblage de culture mycobactérienne pour une bactérie complexe de mycobacterium avium |
| US7807182B2 (en) | 1996-12-31 | 2010-10-05 | Colorado State University Research Foundation | Early detection of mycobacterial disease using peptides |
| US8158371B2 (en) | 2006-09-08 | 2012-04-17 | Wisconsin Alumni Research Foundation | Assay for antibodies to Mycobacterium paratuberculosis |
| JP2014232117A (ja) * | 2012-04-05 | 2014-12-11 | 株式会社ビーエル | 結核菌群の免疫学的検出方法及び検出用キット |
| WO2016012449A1 (fr) * | 2014-07-22 | 2016-01-28 | Tbdiadirect Ab | Anticorps monoclonal, procédé, kit et utilisation |
| US9315566B2 (en) | 2011-01-24 | 2016-04-19 | National University Of Singapore | Pathogenic mycobacteria-derived mannose-capped lipoarabinomannan antigen binding proteins |
| WO2016130638A1 (fr) * | 2015-02-10 | 2016-08-18 | University Of Utah Research Foundation | Procédés de détection d'analytes et de diagnostic de la tuberculose |
| WO2019186486A1 (fr) | 2018-03-29 | 2019-10-03 | Foundation Of Innovative New Diagnostics | Anticorps ou combinaison d'anticorps et procédé l'utilisant permettant la détection d'un antigène associé à une mycobactérie dans un échantillon d'urine d'un sujet |
| CN111337665A (zh) * | 2020-01-16 | 2020-06-26 | 卢氏实验室公司 | 一种用于检测肺结核感染的免疫层析试纸条及其制备方法 |
| WO2021127096A1 (fr) * | 2019-12-17 | 2021-06-24 | National Jewish Health | Méthodes de détection de lipoarabinomannane et de diagnostic d'infection mycobactérienne non tuberculeuse |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0273333A2 (fr) * | 1987-01-02 | 1988-07-06 | Biotest AG | Procédé pour la détection immunologique de mycobactéries dans le crachat et anticorps monoclonaux pour la réalisation de ce procédé |
| WO1992014156A1 (fr) * | 1991-02-12 | 1992-08-20 | Dynagen, Inc. | Test d'immunofluorescence servant a detecter des antigenes mycobacteriens dans des fluides biologiques |
| WO1992014154A1 (fr) * | 1991-02-12 | 1992-08-20 | Dynagen, Inc. | Serodiagnostic d'agglutination destine a des antigenes mycobacteriens dans des echantillons biologiques |
| WO1992014155A1 (fr) * | 1991-02-12 | 1992-08-20 | Dynagen, Inc. | Anticorps monoclonaux diriges contre des antigenes mycobacteriens |
-
1996
- 1996-03-12 SE SE9600949A patent/SE9600949D0/xx unknown
-
1997
- 1997-03-03 AU AU20942/97A patent/AU2094297A/en not_active Abandoned
- 1997-03-03 WO PCT/EP1997/001037 patent/WO1997034149A1/fr active Application Filing
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0273333A2 (fr) * | 1987-01-02 | 1988-07-06 | Biotest AG | Procédé pour la détection immunologique de mycobactéries dans le crachat et anticorps monoclonaux pour la réalisation de ce procédé |
| WO1992014156A1 (fr) * | 1991-02-12 | 1992-08-20 | Dynagen, Inc. | Test d'immunofluorescence servant a detecter des antigenes mycobacteriens dans des fluides biologiques |
| WO1992014154A1 (fr) * | 1991-02-12 | 1992-08-20 | Dynagen, Inc. | Serodiagnostic d'agglutination destine a des antigenes mycobacteriens dans des echantillons biologiques |
| WO1992014155A1 (fr) * | 1991-02-12 | 1992-08-20 | Dynagen, Inc. | Anticorps monoclonaux diriges contre des antigenes mycobacteriens |
Non-Patent Citations (3)
| Title |
|---|
| E SADA ET AL.: "Detection of lipoarabinomannan as a diagnostic test for tuberculosis.", JOURNAL OF CLINICAL MICROBIOLOGY, vol. 30, no. 9, September 1992 (1992-09-01), pages 2415 - 2418, XP002035611 * |
| S. N. CHO ET AL.: "Detection of Mycobacterium tuberculosis antigens in sputum samples from tuberculosis patients.", ABSTRACTS OF THE GENERAL MEETING OF THE AMERICAN SOCIETY FOR MICROBIOLOGY, vol. 94, no. 0, 23 May 1994 (1994-05-23) - 27 May 1994 (1994-05-27), pages 174, XP002035609 * |
| S.N. CHO ET AL.: "Production of monoclonal antibodies to lipoarabinomannan-B and use in the detection of mycobacterial antigens in sputum.", YONSEI MEDICAL JOURNAL, vol. 31, no. 4, 1990, pages 333 - 338, XP002035610 * |
Cited By (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0952849A4 (fr) * | 1996-12-31 | 2004-09-08 | Univ New York | Depistage precoce des maladies mycobacteriennes |
| US7807182B2 (en) | 1996-12-31 | 2010-10-05 | Colorado State University Research Foundation | Early detection of mycobacterial disease using peptides |
| EP0952849A1 (fr) * | 1996-12-31 | 1999-11-03 | New York University | Depistage precoce des maladies mycobacteriennes |
| EP1158991A1 (fr) * | 1999-03-15 | 2001-12-05 | The Malaghan Institute of Medical Research | Traitement de l'asthme |
| EP1158991A4 (fr) * | 1999-03-15 | 2003-05-14 | Malaghan Inst Of Medical Res | Traitement de l'asthme |
| WO2001027613A3 (fr) * | 1999-10-12 | 2001-10-18 | Connex Ges Zur Optimierung Von | Procede de detection ameliore de micro-organismes acido-resistants dans les selles |
| EP1336850A1 (fr) * | 1999-10-12 | 2003-08-20 | Connex Gesellschaft zur Optimierung von Forschung und Entwicklung | Procédé de détection amélioré de micro-organismes acido-résistants dans les selles |
| EP1329718A3 (fr) * | 2002-01-10 | 2004-06-02 | Becton, Dickinson and Company | Methodes et appareils pour rassembler et preparer des echantillons afin de detecter des mycobacteries et leurs antigenes |
| EP1780547A1 (fr) * | 2002-01-10 | 2007-05-02 | Becton, Dickinson and Company | Methodes et appareils pour rassembler et preparer des echantillons afin de detecter des mycobacteries et leurs antigenes |
| EP1329718A2 (fr) * | 2002-01-10 | 2003-07-23 | Becton, Dickinson and Company | Methodes et appareils pour rassembler et preparer des echantillons afin de detecter des mycobacteries et leurs antigenes |
| US8703412B2 (en) | 2003-12-22 | 2014-04-22 | Seikagaku Corporation | Method of measuring lipoarabinomannan and application thereof |
| EP1710584A1 (fr) * | 2003-12-22 | 2006-10-11 | Seikagaku Corporation | Procede permettant de mesurer le lipoarabinomannane et applications de ce procede |
| EP1710584A4 (fr) * | 2003-12-22 | 2007-11-14 | Seikagaku Kogyo Co Ltd | Procede permettant de mesurer le lipoarabinomannane et applications de ce procede |
| US7851179B2 (en) | 2003-12-22 | 2010-12-14 | Seikagaku Corporation | Method of measuring lipoarabinomannan and application thereof |
| EA013228B1 (ru) * | 2004-07-20 | 2010-04-30 | Чемоджен, Инк. | Способ получения обогащённого поликлонального антитела, высокоспецифичного к антигену поверхностного полисахарида липоарабиноманнана микобактерий, и способы его применения |
| US7615222B2 (en) | 2004-07-20 | 2009-11-10 | Chemogen, Inc. | Enriched antibody for detecting mycobacterial infection, methods of use and diagnostic test employing same |
| US7335480B2 (en) | 2004-07-20 | 2008-02-26 | Chemogen, Inc. | Enriched antibody for detecting mycobacterial infection, methods of use and diagnostic test employing same |
| AP2316A (en) * | 2004-07-20 | 2011-11-04 | Chemogen Inc | Enriched antibody for detecting mycobacterial infection, methods of use and diagnostic test employing same. |
| US8057797B2 (en) | 2004-07-20 | 2011-11-15 | Chemogen, Inc. | Method of preparing enriched antibodies for detecting mycobacterial infection |
| WO2006012413A1 (fr) | 2004-07-20 | 2006-02-02 | Chemogen, Inc. | Anticorps enrichi pour detecter une infection mycobacterienne, procedes pour l'utiliser et test diagnostique utilisant celui-ci |
| WO2008011927A3 (fr) * | 2006-07-27 | 2008-03-13 | Jordanian Pharmaceutical Mfg | Coupelle pour détection immunochromatographiqe d'antigènes |
| WO2008011927A2 (fr) * | 2006-07-27 | 2008-01-31 | The Jordanian Pharmaceutical Manufacturing Co. | Coupelle pour détection immunochromatographiqe d'antigènes |
| EP1882939A1 (fr) * | 2006-07-27 | 2008-01-30 | The Jordanian Pharmaceutical Manufacturing Co. | Ventouse de détection antigène immuno-chromatographique urinaire |
| US8158371B2 (en) | 2006-09-08 | 2012-04-17 | Wisconsin Alumni Research Foundation | Assay for antibodies to Mycobacterium paratuberculosis |
| WO2009117462A1 (fr) * | 2008-03-18 | 2009-09-24 | Wisconsin Alumini Research Foundation | Test de criblage de culture mycobactérienne pour une bactérie complexe de mycobacterium avium |
| US8153383B2 (en) | 2008-03-18 | 2012-04-10 | Wisconsin Alumni Research Foundation | Mycobacterial culture screening test for Mycobacterium avium complex bacteria |
| US9315566B2 (en) | 2011-01-24 | 2016-04-19 | National University Of Singapore | Pathogenic mycobacteria-derived mannose-capped lipoarabinomannan antigen binding proteins |
| EP2835646A4 (fr) * | 2012-04-05 | 2015-12-02 | Bl Co Ltd | Procédé et kit pour la détection immunologique de complexe mycobacterium tuberculosis |
| JP2014232117A (ja) * | 2012-04-05 | 2014-12-11 | 株式会社ビーエル | 結核菌群の免疫学的検出方法及び検出用キット |
| EP3093667A1 (fr) * | 2012-04-05 | 2016-11-16 | BL Co., Ltd | Procede et kit pour la detection immunologique de complexe mycobacerium tuberculosis |
| EP3499237A1 (fr) * | 2012-04-05 | 2019-06-19 | Tauns Co., Ltd. | Procédé et kit de détection de immunologique du complexe de mycobacterium tuberculosis |
| US10823730B2 (en) | 2012-04-05 | 2020-11-03 | Tauns Co., Ltd. | Method and kit for immunological detection of Mycobacterium tuberculosis |
| US10830769B2 (en) | 2012-04-05 | 2020-11-10 | Tauns Co., Ltd | Method and kit for immunological detection of Mycobacterium tuberculosis |
| US10883988B2 (en) | 2012-04-05 | 2021-01-05 | Tauns Co., Ltd. | Method and kit for immunological detection of Mycobacterium tuberculosis complex |
| WO2016012449A1 (fr) * | 2014-07-22 | 2016-01-28 | Tbdiadirect Ab | Anticorps monoclonal, procédé, kit et utilisation |
| WO2016130638A1 (fr) * | 2015-02-10 | 2016-08-18 | University Of Utah Research Foundation | Procédés de détection d'analytes et de diagnostic de la tuberculose |
| WO2019186486A1 (fr) | 2018-03-29 | 2019-10-03 | Foundation Of Innovative New Diagnostics | Anticorps ou combinaison d'anticorps et procédé l'utilisant permettant la détection d'un antigène associé à une mycobactérie dans un échantillon d'urine d'un sujet |
| WO2021127096A1 (fr) * | 2019-12-17 | 2021-06-24 | National Jewish Health | Méthodes de détection de lipoarabinomannane et de diagnostic d'infection mycobactérienne non tuberculeuse |
| CN111337665A (zh) * | 2020-01-16 | 2020-06-26 | 卢氏实验室公司 | 一种用于检测肺结核感染的免疫层析试纸条及其制备方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2094297A (en) | 1997-10-01 |
| SE9600949D0 (sv) | 1996-03-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO1997034149A1 (fr) | Methode diagnostique de mycobacteriose et trousse d'essai immunologique | |
| JP2667695B2 (ja) | 試料中のエンドトキシンの存在を決定する方法 | |
| Davin et al. | Anti-α-galactosyl antibodies and immune complexes in children with Henoch–Schönlein purpura or IgA nephropathy | |
| JP3043999B2 (ja) | 排泄物検体中のｈ．ピロリ菌のイムノアッセイ | |
| AU740158B2 (en) | Beta(1-3)-glucan diagnostic assays | |
| JP2944721B2 (ja) | エンドトキシンの測定剤 | |
| JP2002525632A (ja) | 癌の標識及び予後指標としてのｙｋｌ−４０ | |
| JP2006284567A (ja) | ヘリコバクター・ピロリ感染の診断方法及び診断キット | |
| JPS6120867A (ja) | 抗体‐レクチンのサンドイツチ検定 | |
| EP0255342B1 (fr) | Méthode de détection ou d'estimation de matière biologique | |
| CN113574065B (zh) | 生物样品中β-D-葡聚糖的免疫测定方法，以及β-D-葡聚糖的测定试剂盒 | |
| US5098826A (en) | Detection, isolation and purification of Clostridium difficile toxin A with toxin receptors | |
| US8241857B2 (en) | Method for detection of pneumococcus | |
| EP0313244B1 (fr) | Procédé pour augmenter la sensibilité de tests pour la mucine | |
| JPS6057254A (ja) | 免疫学的測定法による糖脂質の定量方法 | |
| US4789631A (en) | Immunoassay for anti-dirofilaria immitis antibody | |
| Radhakrishnan et al. | Detection of Mycobacterium tuberculosis antigen 5 in cerebrospinal fluid by inhibition ELISA and its diagnostic potential in tuberculous meningitis | |
| JP3730919B2 (ja) | ベロトキシン産生大腸菌に起因する腎障害、溶血性尿毒症症候群および腸管出血性大腸菌感染症の検査方法 | |
| JP4071330B2 (ja) | 抗ヒトメダラシンモノクローナル抗体、その製造方法及びそれを用いる免疫学的測定方法 | |
| US6235487B1 (en) | Method of diagnosing Crohn's disease | |
| WO1997026007A1 (fr) | Antigenes mycobacteriens et leurs procedes de detection | |
| Lim et al. | DIAGNOSIS OF ENTERIC FEVER BY INHIBITION ASSAY USING PEROXIDASE‐LABELLED MONOCLONAL ANTIBODY AND SALMONELLA TYPHI LIPOPOLYSACCHARIDE | |
| EP0782863B1 (fr) | Reactif anticorpal pour la detection des anevrismes dissequants de l'aorte et utilisation de ce reactif | |
| JP2004069672A (ja) | 酸化アポリポタンパク質ａｉ及びそれを含有する酸化リポタンパク質の測定法及びキット | |
| Tyler et al. | Cross-reactive affinity purification of immunoglobulin recognizing common gram-negative bacterial core antigens |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AU BA BB BG BR CA CN CU CZ EE GE HU IL IS JP KP KR LC LK LR LT LV MG MK MN MX NO NZ PL RO SG SI SK TR TT UA US UZ VN AM AZ BY KG KZ MD RU TJ TM |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| NENP | Non-entry into the national phase |
Ref country code: CA |
|
| NENP | Non-entry into the national phase |
Ref country code: JP Ref document number: 97532239 Format of ref document f/p: F |
|
| 122 | Ep: pct application non-entry in european phase |